Cargando…

Morbidity and mortality in schizophrenia with comorbid substance use disorders

OBJECTIVE: Schizophrenia is highly comorbid with substance use disorders (SUD) but large epidemiological cohorts exploring the prevalence and prognostic significance of SUD are lacking. Here, we investigated the prevalence of SUD in patients with schizophrenia in Finland and Sweden, and the effect o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lähteenvuo, Markku, Batalla, Albert, Luykx, Jurjen J., Mittendorfer‐Rutz, Ellenor, Tanskanen, Antti, Tiihonen, Jari, Taipale, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359349/ https://www.ncbi.nlm.nih.gov/pubmed/33650123 http://dx.doi.org/10.1111/acps.13291

Ejemplares similares

Morbidity and mortality in schizophrenia with comorbid substance use disorders in Finland and Sweden
por: Lähteenvuo, M., et al.
Publicado: (2021)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2020)

S210. COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS FOR RISK OF ATTEMPTED OR COMPLETED SUICIDE AMONG PERSONS WITH SCHIZOPHRENIA
por: Taipale, Heidi, et al.
Publicado: (2020)

T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
por: Lähteenvuo, Markku, et al.
Publicado: (2020)

Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
por: Heikkinen, Milja, et al.
Publicado: (2021)

Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
por: Lintunen, Jonne, et al.
Publicado: (2021)

Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
por: Heikkinen, Milja, et al.
Publicado: (2022)

Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
por: Heikkinen, Milja, et al.
Publicado: (2022)

Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
por: Lieslehto, Johannes, et al.
Publicado: (2023)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
por: Lintunen, Jonne, et al.
Publicado: (2021)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
por: Holm, Minna, et al.
Publicado: (2020)

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
por: Puranen, Arto, et al.
Publicado: (2023)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study
por: Paljärvi, Tapio, et al.
Publicado: (2023)

Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
por: Taipale, Heidi, et al.
Publicado: (2020)

Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2020)

Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2022)

Twenty‐year medication use trends in first‐episode bipolar disorder
por: Poranen, Juulia, et al.
Publicado: (2022)

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
por: Taipale, Heidi, et al.
Publicado: (2022)

Effects of Substance Use and Antisocial Personality on Neuroimaging-Based Machine Learning Prediction of Schizophrenia
por: Taipale, Matias, et al.
Publicado: (2023)

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis
por: Hamina, Aleksi, et al.
Publicado: (2020)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Initiation of antidepressant use among refugee and Swedish-born youth after diagnosis of a common mental disorder: findings from the REMAIN study
por: Taipale, Heidi, et al.
Publicado: (2020)

The clinical course of schizophrenia in women and men—a nation-wide cohort study
por: Sommer, Iris E., et al.
Publicado: (2020)

Patient factors associated with receipt of psychological and pharmacological treatments among individuals with common mental disorders in a Swedish primary care setting
por: Cullen, Alexis E., et al.
Publicado: (2023)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Substance Abuse and Excessive Mortality Among Forensic Psychiatric Patients: A Finnish Nationwide Cohort Study
por: Ojansuu, Ilkka, et al.
Publicado: (2019)

Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
por: Mittendorfer-Rutz, Ellenor, et al.
Publicado: (2014)

Antidepressant use and psychosis hospitalization in persons with schizophrenia
por: Puranen, A., et al.
Publicado: (2023)

Labour market marginalisation in young adults diagnosed with attention-deficit hyperactivity disorder (ADHD): a population-based longitudinal cohort study in Sweden
por: Helgesson, Magnus, et al.
Publicado: (2023)

Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
por: Tiihonen, Miia, et al.
Publicado: (2016)

Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
por: Sommer, Iris E, et al.
Publicado: (2022)

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Risk Factors for Disability Pension among Young Adults Diagnosed with Attention-deficit Hyperactivity Disorder (ADHD) in Adulthood
por: Chen, Lingjing, et al.
Publicado: (2021)

Occupational Branch and Labor Market Marginalization among Young Employees with Adult Onset of Attention Deficit Hyperactivity Disorder—A Population-Based Matched Cohort Study
por: Gémes, Katalin, et al.
Publicado: (2022)

Antipsychotic treatment patterns in refugees and their Swedish-born peers with first-episode non-affective psychosis: findings from the REMAIN study
por: Spaton Goppers, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6vlr8j4so20blturb98jjmh9f0